Skip to main content

Table 1 Patient and pathology characteristics

From: Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

Patient no

Age at OTC

Type of leukemia

Treatment received before OTC

LAIP identified at diagnosis

Molecular marker at diagnosis

IV, IM or per os

IT

CED

DIE

1

29

B-ALL

1, 2, 11, 15, 18

1, 11, 14

0

0

CD10 (100%), CD19 (100%), CD20 (87%0, CD22 (100%), CD34 (78%), CD38 (100%), CD58 (100%), CD200 (62%), CD304 (78%), cMPO (81%), oCD22 (99%), cTDT (73%), cCD79a (99%)

BCR-ABL1

2

31

B-ALL

1, 2, 3, 4, 5, 6, 11, 12

1, 11, 14

2 500

175

CD19 (100%), CD22 (96%), cyCD22 (94), CD34 (100%), CD38 (99%), CD44 (98%), CD58 (98%), CD123 (99%), cyTDT (90%), cyCD79a (94%)

Ig/TCR

3

14

B-ALL

1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15

1, 11, 14

1 464

191

CD19 (91%), CD34 (87%), negative for CD10 and myeloid markers

Ig/TCR

4

12

B-ALL

1, 2, 3, 5, 6, 11

1, 11, 19

0

24

CD45 (88%), HLA DRII (88%), CD10 (78%), CD19 (78%), CD22 (82%), CD33 (35%)

Ig/TCR

5

5

B-ALL

1, 2, 3, 4, 5, 6, 7, 9, 19, 11, 12, 13, 14, 15

1, 11, 14, 19

2 500

314

CD19 (86%), CD10 (98%), CD22 (90%) CD38 (99%)

Unkown

6

5

B-ALL

1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 14, 15

1, 11, 19

610

87

CD45 (12%), CD10 (87%), CD19 (79%), CD22 (86%), CD34 (70%) HLA-DRII (81%)

Ig/TCR

7

14

T-ALL

1, 2, 3, 4, 6, 11, 12, 15, 20

1, 11, 14

2 000

100

CD2 (89%), cyCD3 (94%), CD5 (93%), CD7 (98%), CD10 (49%), CD33 (81%), CD34 (89%), CD45RA (99%), CD123 (56%)

None

8

22

T-ALL

1, 2, 3, 4, 6, 16

1, 11, 14

1 000

133

CD2 (76%), CD7 (94%), CD13 (98%), CD10 (80%), cyCD3 (83%), cyCD79 (80%)

None

9

33

AML

1, 3, 17

1, 11, 14

0

300

CD13 (100%), cyCD13 (100%), CD15 (55%), CD33 (100%), CD34 (100%), CD38 (100%), CD117 (100%), cMPO (100%)

CBFB-MYH11

10

15

AML

1

1, 11, 19

0

373

CD34 (96%), CD33 (98%), CD13 (54,5%), CD117 (47%), CD38 (40,5%)

WT1

11

22

AML

1, 3, 17

1, 11,14

0

300

CD7 (80%), CD11b (83%), CD13 (96%), cCD13 (66%), CD19 (51%), CD33 (96%), CD34 (100%), CD38 (100%), CD71 (93%), CD117 (100%), cyMPO (100%), HLA DR (92%)

WT1

12

15

AML

1, 13

1, 11, 19

0

240

CD13 (90%), CD33 (99%), CD117 (99%), CD65 (86%), CD7 (99%), HLA DR2 (97%), CD34 (98%), CD38 (98%)

CEBPA mutations

13

14

AML

1, 13, 16

1, 11, 19

0

48

CD13 (100%), CD33 (100%), CD65 (100%), CD117 (100%), et CD11c (100%)

Unknown

14

26

AML

None

None

0

0

CD13 (100%), CD33 (100%), CD117 (100%), CD34 (100%), CD38 (100%), CD123 (89%), cyMPO (100%), cyCD13 (100%)

None

15

27

AML

1, 4, 14, 15, 16, 17, 21

None

0

225

CD34 (100%), CD33 (50%), CD38 (100%), HLA DR (100%), CD99 (50)

BCR-ABL1

  1. OTC ovarian tissue cryopreservation, MRD minimal residual disease, LAIP leukemia-associated immunophenotype, IV intravenous, IM intramuscular, IT intrathecal, CED cyclophosphamide equivalent dose, DIE doxorubicin isotoxic equivalent, B-ALL B-cell acute lymphoblastic leukemia, T-ALL T-cell acute lymphoblastic leukemia, AML acute myeloid leukemia, Ig immunoglobulin rearrangement genes, TCR T-cell receptor rearrangement genes
  2. 1 indicates cytarabine, 2 vincristine, 3 daunorubicin, 4 cyclophosphamide, 5 etoposide, 6 asparaginase, 7 doxorubicin, 8 ifosfamide, 9 thioguanine, 10 vindesine, 11 methotrexate, 12 mercaptopurine, 13 mitoxantrone, 14 prednisolone, 15 dexamethasone, 16 amsacrine, 17 idarubicin, 18 imatinib, 19 hydrocortisone, 20 vinblastine, 21 gemtuzumab
  3. See Additional file 1 for CED and DIE calculation
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us